<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METHENAMINE HIPPURATE- methenamine hippurateÂ tabletÂ </strong><br>CorePharma, LLC<br></p></div>
<h1>METHENAMINE HIPPURATE TABLETS USP <br>1 g <br><br>Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9c9837f1-6c74-419e-a68f-02e19afe9c5f"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness ofÂ methenamine hippurate tablets, USPÂ and other antibacterial drugs, methenamine hippurate tablets, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_9e3a126f-2cf7-40d5-83e0-c24c37079332"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">Methenamine hippurate tablets, USP are available as 1 g oval shaped, scored and peach colored tablets. Chemically, methenamine hippurate is Hexamethylene-tetramine monohippurate. The molecular formula of methenamine hippurate is C<span class="Sub">15</span>H<span class="Sub">21</span>N<span class="Sub">5</span>O<span class="Sub">3</span> and molecular weight is 319.36. Its structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure - Methenamine Hippurate Tablets 1 gm" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad741dc5-816c-4ab2-9273-9b1a586149bc&amp;name=methenamine-hippurate-tablets-1.jpg"></div>
<p>EachÂ methenamine hippurate tablets, USP intended for oral administration contains 1 g of methenamine hippurate. In addition, it also contains the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, povidone K29/32, saccharin sodium and FD&amp;C Yellow #6 Aluminum Lake as a color additive.</p>
<p>Meets USP Dissolution Test 2.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_e8bb6b89-c61c-45f8-979c-d50e2952f973"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">ACTIONS </span></h1>
<p class="First"><span class="Bold">Microbiology: </span>MethenamineÂ hippurate tablets,Â USP has antibacterial activity because the methenamine component is hydrolyzed to formaldehyde in acid urine. Hippuric acid, the other component, has some antibacterial activity and also acts to keep the urine acid. The drug is generally active against <span class="Italics">E. coli</span>, enterococci and staphylococci. <span class="Italics">Enterobacter aerogenes</span> is generally resistant. The urine must be kept sufficiently acid for urea-splitting organisms such as <span class="Italics">Proteus</span> and <span class="Italics">Pseudomonas</span> to be inhibited.</p>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_c2cf98a1-24ec-42dc-b25c-75c0ca9a0d9c"></a><a name="section-3.1"></a><p></p>
<h2><span class="Bold">Human Pharmacology</span></h2>
<p class="First">Within 1/2 hour after ingestion of a single 1-gram dose of methenamine hippurate, USP, antibacterial activity is demonstrable in the urine. Urine has continuous antibacterial activity whenÂ methenamine hippurate tablets,Â USP is administered at the recommended dosage schedule of 1 gram twice daily. Over 90% of methenamine moiety is excreted in the urine within 24 hours after administration of a single 1-gram dose. Similarly, the hippurate moiety is rapidly absorbed and excreted, and it reaches the urine by both tubular secretion and glomerular filtration. This action may be important in older patients or in those with some degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_3c86ec6b-588a-417f-ae10-3529c355412a"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS</span></h1>
<p class="First">Methenamine hippurate tablets, USP are indicated for <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> or suppressive treatment of frequently recurring <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> when long-term therapy is considered necessary. This drug should only be used after eradication of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> by other appropriate antimicrobial agents.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets, USP and other antibacterial drugs, methenamine hippurate tablets, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_6369a7db-ebbc-4874-9703-bb2229bcd4fc"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First">MethenamineÂ hippurate tablets, USP are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, or severe <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. Methenamine preparations should not be given to patients taking sulfonamides because some sulfonamides may form an insoluble precipitate with formaldehyde in the urine.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_b52c257c-3546-4d89-8f8f-c1e92538cf61"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First">Large doses of methenamine (8 grams daily for 3 to 4 weeks) have caused <span class="product-label-link" type="condition" conceptid="4227848" conceptname="Bladder irritability">bladder irritation</span>, painful and frequent micturition, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, and gross <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_4f0c9a01-bc04-4272-87de-b0fd4e978795"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<p class="First">PrescribingÂ methenamine hippurate tablets,Â USP in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>1.Â  Care should be taken to maintain an acid pH of the urine, especially when treating <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to urea-splitting organisms such as<span class="Italics">Â Â Â  <br>Â Â Â Â  Proteus</span> and <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Pseudomonas</span>.</p>
<p>2.Â  In a few instances in one study, the serum transaminase levels were slightly elevated during treatment but returned to normal while <br>Â Â Â Â  the patients were still takingÂ methenamine hippurate tablets,Â USP. Because of this report, it is recommended that liver function studies <br>Â Â Â Â  be performed periodically on patients taking the drug, especially those with liver dysfunction.</p>
<p>3.Â  Use in Pregnancy: In early pregnancy the safe use of methenamine hippurate tablets, USP is not established. In the last trimester, <br>Â Â Â Â  safety is suggested, but not definitely proved. No adverse effects on the fetus were seen in studies in pregnant rats and rabbits.<br>Â Â Â Â <br>Â Â Â Â Â MethenamineÂ hippurate tablets,Â USP taken during pregnancy can interfere with laboratory tests of urine estriol (resulting inÂ  <br>Â Â Â Â  unmeasurably low values) when acid hydrolysis is used in the laboratory procedure. This interference is due to the presence inÂ Â <br>Â Â Â Â Â theÂ urine of methenamine and/or formaldehyde. Enzymatic hydrolysis, in place of acid hydrolysis, will circumvent this problem.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_79c31b7b-86a2-4210-bbe9-29924eb66fd2"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold"><span class="Underline">Information for Patients</span></span></h2>
<p class="First">Patients should be counseled that antibacterial drugs including methenamine hippurate tablets, USP should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). WhenÂ methenamine hippurate tablets,Â USP are prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable byÂ methenamine hippurate tablets, Â USP or other antibacterial drugs in the future.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d1f14c17-9f12-4ce9-a789-40decfab9424"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold">Geriatric Use</span></h2>
<p class="First">Clinical studies ofÂ methenamine hippurate tablet, USPÂ did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>MethenamineÂ hippurate tablets, USPÂ Â are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. (seeÂ <span class="Bold"><a href="#LINK_6369a7db-ebbc-4874-9703-bb2229bcd4fc">CONTRAINDICATIONS</a></span> ).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_7074d84a-ab63-414f-8cf5-5271c4642bb3"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<p class="First">Minor adverse reactions have been reported in less than 3.5% of patients treated. These reactions have included <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_6796adb7-2b6b-4954-bca7-039eb7f62d24"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">1 tablet (1 g) twice daily (morning and night) for adults and pediatric patients over 12 years of age. 1/2 to 1 tablet (0.5 to 1 g) twice daily (morning and night) for pediatric patients 6 to 12 years of age. Since the antibacterial activity of methenamine hippurate tablets, USP is greater in acid urine, restriction of alkalinizing foods and medications is desirable. If necessary, as indicated by urinary pH and clinical response, supplemental acidification of the urine should be instituted. The efficacy of therapy should be monitored by repeated urine cultures.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_c46eda78-4349-4fd9-9475-ad76ac9cc9cd"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<p class="First">MethenamineÂ hippurate tablets, Â USP 1 g are supplied as peach, oval shaped compressed tablets debossed â€œ<span class="Bold">cor</span>â€? on the left and â€œ<span class="Bold">139</span>â€? on the right side of bisect on one side and other side is plain.</p>
<p>Methenamine hippurate tablets, USP 1 g are supplied:</p>
<p>Bottles of 100Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  (NDC 64720-139-10)</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_c2f5aa39-6af4-4139-91ec-b33e587308d9"></a><a name="section-11"></a><p></p>
<h1></h1>
<p class="First">Store atÂ  20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
<p>Dispense in well-closed, light-resistant containers with child-resistant closures.<br><br><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad741dc5-816c-4ab2-9273-9b1a586149bc&amp;name=methenamine-hippurate-tablets-2.jpg"><br><br>Manufactured by: <br>CorePharma LLC <br>Middlesex, NJ 08846<br><br>LB# 745-02Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Rev.Â  December, 2010</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_a526bf3a-890c-4bcf-a41e-6f22c187c566"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<div class="Figure"><img alt="Methenamine Hippurate Tablets, USP, 1 g" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad741dc5-816c-4ab2-9273-9b1a586149bc&amp;name=methenamine-hippurate-tablets-3.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METHENAMINE HIPPURATEÂ 		
					</strong><br><span class="contentTableReg">methenamine hippurate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64720-139</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHENAMINE HIPPURATE</strong> (METHENAMINE) </td>
<td class="formItem">METHENAMINE HIPPURATE</td>
<td class="formItem">1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K29/32</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (oval) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">cor;139</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64720-139-10</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076411</td>
<td class="formItem">07/01/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>CorePharma, LLC
							(031192276)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>07fc196d-df18-4ab2-91df-e584cbd00398</div>
<div>Set id: ad741dc5-816c-4ab2-9273-9b1a586149bc</div>
<div>Version: 8</div>
<div>Effective Time: 20140324</div>
</div>
</div>Â <div class="DistributorName">CorePharma, LLC</div></p>
</body></html>
